Drug Trial Radar · NCT05614063
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
380
Actual
Start
Nov 18, 2022
Primary completion
Jan 12, 2026
Study completion Feb 3, 2026
Sponsor
- Lead sponsor
- Xenon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Nov 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Conditions
- Focal Onset Seizures
Interventions
XEN1101Drug
XEN1101 Capsules
PlaceboDrug
Placebo Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.Time frame: From baseline through to the double blind period (week 12)
Locations
125 sites in 18 countries. Site status is shown where the registry gives one.
Strada Patient Care Center
Mobile, Alabama
Xenoscience
Phoenix, Arizona
University of Arizona, Health Sciences Center
Tucson, Arizona
Clinical Trials, Inc
Little Rock, Arkansas
Brain Science Research Institute
Los Angeles, California
University of California, David Clinical & Translational Science Center Clinical Research (CCRC)
Sacramento, California
Anschutz Health Sciences
Aurora, Colorado
Serenity Research
Miami, Florida
Research Institute of Orlando, LLC
Orlando, Florida
Panhandle Research & Medical Clinic
Pensacola, Florida
Medsol Clinical Research Center
Port Charlotte, Florida
University of South Florida
Tampa, Florida
Encore Medical Research of Weston, LLC
Weston, Florida
Emory Brain Health Center
Atlanta, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology
Boise, Idaho
Indiana University, IU Health Partners, Adult Neurology Clinic
Indianapolis, Indiana
The University of Kansas Medical Center
Kansas City, Kansas
Bluegrass Epilepsy Research, LLC
Lexington, Kentucky
University of Kentucky, Dept. of Neurology
Lexington, Kentucky
MaineHealth Neurology - Scarborough
Scarborough, Maine
University of Maryland Medical Center
Baltimore, Maryland
Medstar Franklin Square Medical Center
Baltimore, Maryland
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
MedStar Georgetown University Hospital
Clinton, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Michigan State University
East Lansing, Michigan
Cornwell Health
Grand Rapids, Michigan
Minneapolis Clinic of Neurology
Burnsville, Minnesota
Saint Louis University Medical School - Neurosciences Clinical Research Unit
St Louis, Missouri
Washington University, St. Louis
St Louis, Missouri
Northeast Epilepsy Group
Hackensack, New Jersey
Dent Neurosciences Research Center
Buffalo, New York
NYU Comprehensive Epilepsy Center (CEC)
New York, New York
Weill Cornell Medicine/ New York-Presbyterian Hospital
New York, New York
Mount Sinai Medical Center
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Montefiore Medical Center
The Bronx, New York
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.